Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Two Cases of Myeloproliferative Neoplasm with a Concurrent $JAK2^{V617F}$ Mutation and BCR/ABL Translocation without Chronic Myelogenous Leukemia Phenotype Acquisition during Hydroxyurea Treatment

  • Park, Sang Hyuk (Department of Laboratory Medicine, University of Ulsan, College of Medicine and Asan Medical Center) ;
  • Chi, Hyun-Sook (Department of Laboratory Medicine, University of Ulsan, College of Medicine and Asan Medical Center) ;
  • Cho, Young-Uk (Department of Laboratory Medicine, University of Ulsan, College of Medicine and Asan Medical Center) ;
  • Jang, Seongsoo (Department of Laboratory Medicine, University of Ulsan, College of Medicine and Asan Medical Center) ;
  • Park, Chan-Jeoung (Department of Laboratory Medicine, University of Ulsan, College of Medicine and Asan Medical Center) ;
  • Kim, Dae-Young (Department of Internal Medicine, Division of Hematology, University of Ulsan, College of Medicine and Asan Medical Center) ;
  • Lee, Je-Hwan (Department of Internal Medicine, Division of Hematology, University of Ulsan, College of Medicine and Asan Medical Center) ;
  • Lee, Kyoo-Hyung (Department of Internal Medicine, Division of Hematology, University of Ulsan, College of Medicine and Asan Medical Center)
  • Published : 2013.05.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Tefferi A and Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22. https://doi.org/10.1038/sj.leu.2404955
  2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press, 2008.
  3. Hummel JM, Kletecka MC, Sanks JK, Chiselite MD, Roulston D, Smith LB, et al. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms. Diagn Mol Pathol 2012;21:176-83. https://doi.org/10.1097/PDM.0b013e318246975e
  4. Véronèse L, Tchirkov A, Richard-Pebrel C, Ledoux-Pilon A, Fleury J, Chaleteix C, et al. A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm. Leuk Res 2010;34:e94-6. https://doi.org/10.1016/j.leukres.2009.09.025
  5. Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 2007;21: 1103-4. https://doi.org/10.1038/sj.leu.2404591
  6. Campiotti L, Appio L, Solbiati F, Ageno W, Venco A. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. Leuk Res 2009; 33:e212-3. https://doi.org/10.1016/j.leukres.2009.06.011
  7. Kim YK, Shin MG, Kim HR, Yang DH, Cho SH, Lee JJ, et al. Simultane ous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders. Leuk Res 2008;32:993-5. https://doi.org/10.1016/j.leukres.2007.10.018
  8. Bee PC, Gan GG, Nadarajan VS, Latiff NA, Menaka N. A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders. Int J Hematol 2010;91:136-9. https://doi.org/10.1007/s12185-009-0471-6
  9. Bocchia M, Vannucchi AM, Gozzetti A, Guglielmelli P, Poli G, Crupi R, et al. Insights into JAK2-V617F mutation in CML. Lancet Oncol 2007; 8:864-6. https://doi.org/10.1016/S1470-2045(07)70295-4
  10. Jallades L, Hayette S, Tigaud I, Johnston A, Coiffier B, Magaud JP, et al. Emergence of therapy-unrelated CML on a background of BCR-ABLnegative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res 2008;32:1608-10. https://doi.org/10.1016/j.leukres.2008.03.004
  11. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005;106:2920-1. https://doi.org/10.1182/blood-2005-05-2087
  12. Mirza I, Frantz C, Clarke G, Voth AJ, Turner R. Transformation of polycythemia vera to chronic myelogenous leukemia. Arch Pathol Lab Med 2007;131:1719-24.
  13. Conchon MR, Costa JL, Novaes MM, Dorlhiac-Llacer PE, de Alencar Fischer Chamone D, Bendit I. Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia. Int J Hematol 2008;88:243-5. https://doi.org/10.1007/s12185-008-0131-2
  14. Mizutani S, Kuroda J, Shimizu D, Horiike S, Taniwaki M. Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia. Int J Hematol 2010;91:516-21. https://doi.org/10.1007/s12185-010-0502-3
  15. Xiao X, Zhang Y, Zhang GS, Zheng WL, Xiao L, Liu SF. Coexistence of JAK2V617F mutation and BCR-ABL1 transcript in two Chinese patients with chronic myelogenous leukemia. Acta Haematol 2012;127:47-9. https://doi.org/10.1159/000331564
  16. Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 2007;109:4106-7.
  17. Bornhäuser M, Mohr B, Oelschlaegel U, Bornhäuser P, Jacki S, Ehninger G, et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 2007;21:1824-6. https://doi.org/10.1038/sj.leu.2404730
  18. Krämer A. JAK2-V617F and BCR-ABL--double jeopardy? Leuk Res 2008; 32:1489-90. https://doi.org/10.1016/j.leukres.2008.03.011
  19. Cambier N, Renneville A, Cazaentre T, Soenen V, Cossement C, Giraudier S, et al. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 2008;22:1454-5. https://doi.org/10.1038/sj.leu.2405088
  20. Gattenlohner S, Völker HU, Etschmann B, Einsele H, Müller-Hermelink HK. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2 (V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T). Am J Hematol 2009;84:306-7. https://doi.org/10.1002/ajh.21296

Cited by

  1. Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells vol.7, pp.1, 2013, https://doi.org/10.1186/1756-8722-7-37
  2. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group vol.31, pp.5, 2013, https://doi.org/10.1038/modpathol.2017.182
  3. Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients vol.23, pp.10, 2018, https://doi.org/10.1080/10245332.2018.1498182
  4. Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature vol.7, pp.None, 2013, https://doi.org/10.1177/2324709619832322
  5. Clinical significance of myeloproliferative neoplasms with JAK2 V617F mutations and major BCR-ABL1 translocations: a literature review with case presentation vol.55, pp.1, 2013, https://doi.org/10.5045/br.2020.55.1.62
  6. Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2 -V617F Polycythemia Vera vol.9, pp.1, 2013, https://doi.org/10.14740/jh591
  7. A Rare Case of Essential Thrombocythemia with Coexisting JAK2 and MPL Driver Mutations vol.35, pp.23, 2013, https://doi.org/10.3346/jkms.2020.35.e168
  8. Co-existence of mutations in myeloproliferative neoplasms and their clinical significance: a prognostic approach vol.13, pp.11, 2013, https://doi.org/10.1080/17474086.2020.1819232
  9. Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation? vol.27, pp.7, 2013, https://doi.org/10.1177/1078155221991646